| Code | CSB-RA004935MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Iotivibart, targeting CD4, a glycoprotein predominantly expressed on T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 serves as a critical co-receptor for T cell receptor-mediated antigen recognition, facilitating MHC class II molecule interactions and initiating T cell activation and immune responses. This molecule plays a central role in adaptive immunity and is notably exploited by HIV-1 as a primary entry receptor. Dysregulation of CD4-expressing cell populations is associated with autoimmune disorders, immunodeficiency states, transplant rejection, and various inflammatory conditions.
Iotivibart is a humanized IgG4 monoclonal antibody that selectively binds to CD4, designed to modulate T cell-mediated immune responses. This biosimilar provides researchers with a valuable tool for investigating CD4-dependent immune mechanisms, studying T cell biology, exploring HIV pathogenesis, and evaluating immunomodulatory strategies in preclinical models of autoimmune and inflammatory diseases. The antibody enables detailed examination of CD4's role in immune regulation and disease pathology.
There are currently no reviews for this product.